Status:
COMPLETED
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
Lead Sponsor:
University of Washington
Collaborating Sponsors:
GlaxoSmithKline
National Institutes of Health (NIH)
Conditions:
Herpes Simplex
HIV Infections
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
The primary objective of this research study is to assess if daily valacyclovir therapy for suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in individuals co-in...
Detailed Description
Sexually transmitted diseases and genital ulcer disease (GUD) contribute significantly to the spread of HIV, as their presence is associated with higher rates of HIV acquisition in susceptible individ...
Eligibility Criteria
Inclusion
- HIV seropositive and HSV-2 seropositive
- MSM (men having sex with men)
- 18 years old or older
Exclusion
- Known history of adverse reaction to acyclovir or valacyclovir
- Planned open label use of acyclovir, valacyclovir or famciclovir
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00161434
Start Date
March 1 2003
End Date
June 1 2006
Last Update
January 10 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virology Research Clinic
Seattle, Washington, United States, 98122